Compare Abbott Laboratories (ABT) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Enphase Energy Inc — how do they compare? Abbott Laboratories trades at $109.51 (market cap $187.95B), while Enphase Energy Inc trades at $41.46 (market cap $5.59B). The key difference: Abbott Laboratories is far larger — about 33.6× Enphase Energy Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Enphase Energy Inc pays none. Which is the better fit depends on your goals.
| ABT | ENPH | |
|---|---|---|
Market Cap | $187.95B | $5.59B |
Sector | Health | Technology |
52-Week High | $136.62 | $72.33 |
52-Week Low | $82.57 | $26.12 |
Enterprise Value | $214.96B | $5.23B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Enphase Energy (ENPH) trades at $40.92, down 2.27% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Recent Q2 2026 earnings matched estimates but revenue declined 19.6% year-over-year, reflecting ongoing challenges in U.S. residential demand. The company is expanding its battery and commercial segments, with new product launches like the IQ Battery 10C aiming to drive recovery. Analyst consensus is a 'Buy' with a $45.37 price target, implying potential upside from current levels.
Outlook remains cautious but opportunistic; ENPH's valuation multiples are elevated (P/E 41.88, P/S 4.25), requiring earnings normalization for sustained gains. Key risks include cyclical solar demand, interest rate sensitivity, and competitive pressures. Near-term catalysts hinge on execution in storage and international markets, with the stock offering leverage to a sector rebound if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
